Elacestrant for advanced breast cancer: NICE recommendations and ESR1 testing
Published 20 March 2025
The National Institute for Health and Care Excellence (NICE) has issued recommendations for the use of Elacestrant in treating oestrogen receptor-positive (ER+), HER2-negative advanced breast cancer with an ESR1 mutation.Continue reading





